Drug executives say only their GLP-1 drugs are safe for treating obesity and diabetes as they wage a yearlong campaign to stop independent labs from producing cheaper versions.
Researchers found that the risk of type 2 diabetes varies among young adults. Those with high fasting glucose who qualified for GLP-1 treatment had a higher risk of type 2 diabetes, suggesting that ...
DYNAMIKA™ delivers SOC 2 Type II–certified, AI‑driven imaging workflows, giving pharma and biotech secure, compliant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results